

Press Release

Daiichi Sankyo Announces Global Management Structure and Corporate Officers

Tokyo, Japan - (February 21, 2025) – Daiichi Sankyo Company, Limited today announced its Global Management Structure and appointment of Corporate Officers effective from April 1, 2025.

1. Global Management Structure

CEO

Name	Current Responsibilities* ¹	New Responsibilities
Hiroyuki Okuzawa	Chief Operating Officer (COO)	Chief Executive Officer (CEO)

CxO, Global Corporate Function

Name	Current Responsibilities* ¹	New Responsibilities
Nobuo Murakami	—	Head of Global Corporate Strategy Chief Strategy Officer (CStO)
Stuart Mackey	Head of Global Business Development	Unchanged
Koji Ogawa	Head of Global Corporate Planning & Management Chief Financial Officer (CFO)	Unchanged
James Felix	Head of Global DX Chief Digital Transformation Officer (CDXO)	Unchanged
Takashi Matsumoto	Head of Global HR Chief Human Resources Officer (CHRO)	Unchanged
Naoto Tsukaguchi	Head of Global Legal & IP General Counsel (GC)	Unchanged
Matt Allegrucci	Head of Global Compliance & Risk Management Chief Compliance Officer (CCO)	Unchanged
Naoki Shimizu	Head of Global QA* ² Chief Quality Officer (CQO)	Unchanged

Business Units

Name	Current Responsibilities* ¹	New Responsibilities
Shizuko Ueno	—	Head of Japan Business Unit
Ken Keller	Head of Oncology Business Unit	Unchanged
Oliver Appelhans	Head of EU Specialty Business Unit	Unchanged
Kiminori Nagao	Head of ASCA Business Unit	Unchanged
Paul Diolosa	Head of American Regent Unit	Unchanged
Takahiro Uchida	Head of Daiichi Sankyo Healthcare Unit	Unchanged

Functional Units

Name	Current Responsibilities* ¹	New Responsibilities
Ken Takeshita	Head of Research & Development Unit	Unchanged
Hiroto Kashiwase	Head of Technology Unit	Unchanged
Kento Wada	Head of Clinical Safety & Pharmacovigilance Unit	Unchanged

Internal Audit

Name	Current Responsibilities* ¹	New Responsibilities
Manabu Murata	—	Head of Global Internal Audit

*¹ Responsibilities as CxO, Head of Global Corporate Function or Unit Head under current Global Management Structure

*² QA: Quality Assurance

Special Assignment

Name	Current Responsibilities	New Responsibilities
Koji Ogawa* ³	Dean, DS Academy	Unchanged
Shizuko Ueno* ⁴	Special Assignment on Patient Centricity	Unchanged

- ^{*3} Current Executive Officer, Head of Global Corporate Planning & Management, Chief Financial Officer (CFO)
(Senior Executive Officer, Head of Global Corporate Planning & Management, Chief Financial Officer (CFO),
as of April 1, 2025)
- ^{*4} Current Executive Officer, Head of Medical Affairs Div., Japan Business Unit
(Executive Officer, Head of Japan Business Unit and Head of Medical Affairs Div., Japan Business Unit,
as of April 1, 2025)

2. Corporate Officers (Daiichi Sankyo Company, Limited, as of April 1, 2025)

Name	Current Responsibilities	New Responsibilities
Sunao Manabe	Representative Director, Executive Chairperson and CEO	Representative Director, Executive Chairperson
Hiroyuki Okuzawa	Representative Director, President and COO	Representative Director, President and CEO
Shoji Hirashima	Representative Director, Senior Executive Officer Head of Japan Business Unit ^{*6}	Representative Director
Takashi Fukuoka	Director, Senior Executive Officer Head of Global Corporate Strategy Chief Strategy Officer (CStO)	Director
Takashi Matsumoto ^{*5}	Director, Executive Officer Head of Global HR Chief Human Resources Officer (CHRO)	Director, Senior Executive Officer Head of Global HR Chief Human Resources Officer (CHRO)
Koji Ogawa ^{*5}	Executive Officer Head of Global Corporate Planning & Management Chief Financial Officer (CFO)	Senior Executive Officer Head of Global Corporate Planning & Management Chief Financial Officer (CFO)
Hiroto Kashiwase ^{*5}	Executive Officer Head of Technology Unit Head of Technology Div.	Executive Officer Head of Technology Unit
Nobuo Murakami ^{*5}	Executive Officer Head ^{*7} of Corporate Strategy Dept., Global Corporate Strategy	Executive Officer Head of Global Corporate Strategy Chief Strategy Officer (CStO)
Shizuko Ueno ^{*5}	Executive Officer Head of Medical Affairs Div., Japan Business Unit	Executive Officer Head of Japan Business Unit ^{*6} and Head of Medical Affairs Div., Japan Business Unit
Naoto Tsukaguchi ^{*5}	Corporate Officer Head of Global Legal & IP Head ^{*7} of Legal Affairs Dept. General Counsel (GC)	Executive Officer Head of Global Legal & IP General Counsel (GC)
Kiminori Nagao ^{*5}	Corporate Officer Head of ASCA Business Unit Head of ASCA Business Div.	Executive Officer Head of ASCA Business Unit Head of ASCA Business Div.
Hiroshi Masumoto	Corporate Officer Head ^{*7} of Data Intelligence Dept., Global DX	Executive Officer Head ^{*7} of Data Intelligence Dept., Global DX

Name	Current Responsibilities	New Responsibilities
Akio Sakurai	Corporate Officer Head of Sales & Marketing Div., Japan Business Unit	Corporate Officer Special Assignment on Japan Business
Akihiro Inoguchi	Corporate Officer Head* ⁷ of Development Function, R&D Div.	Unchanged
Toshi Kajiro	Corporate Officer Head* ⁷ of Technology Development Supervisory Dept., Technology Div.	Corporate Officer Head of Compliance Strategy and Excellence, Global Compliance & Risk Management
Hiroya Senda	Corporate Officer Head* ⁷ of Sales Planning Dept., Sales & Marketing Div., Japan Business Unit	Corporate Officer Head of Sales & Marketing Div., Japan Business Unit
Satoru Ogawa	Corporate Officer Head* ⁷ of Secretariat Dept.	Unchanged
Atsushi Tsukamoto	Corporate Officer Head of Therapeutic Area Strategies, Research & Development Unit	Corporate Officer Head* ⁷ of Corporate Strategy & Business Portfolio Dept. and Head* ⁷ of Corporate Strategy Group, Global Corporate Strategy
Tetsuya Iwabuchi	Corporate Officer In charge of Business Development	Unchanged
Koji Sato	Corporate Officer Head of Project Lead & DSI Technology Unit, Technology Unit	Corporate Officer Head of Technology Div. and Head* ⁷ of Technology Planning Supervisory Dept., Technology Div.
Tetsuya Ohira	Corporate Officer Head* ⁷ of Corporate Planning Dept. and Head* ⁷ of Project 4D Management Group, Global Corporate Planning & Management	Unchanged
Koichi Nonaka	Corporate Officer Head* ⁷ of Technology Development & Management Dept., Technology Development Supervisory Dept., Technology Div.	Corporate Officer Head* ⁷ of Technology Development Supervisory Dept., Technology Div.
Hanako Saito	Corporate Officer In charge of QA & CSPV* ⁸	Unchanged
Kenji Shigeta	Corporate Officer Head of Global Oncology Marketing, Oncology Business Unit	Unchanged
Akihiro Tokumoto	Corporate Officer Head* ⁷ of Human Resources Dept., Global HR	Unchanged
Junichi Ashihara	Corporate Officer Head* ⁷ of Japan Plant Management Supervisory Dept., Technology Div.	Unchanged

Name	Current Responsibilities	New Responsibilities
Hideaki Noji	Corporate Officer Head* ⁷ of Business Management Dept., Japan Business Unit	Unchanged
Yuki Abe	Corporate Officer Head of R&D Div. and Head* ⁷ of Research Function, R&D Div.	Unchanged
Nobuya Ikeda	Head* ⁷ of Asset & Portfolio Management Dept., R&D Div.	Corporate Officer Head* ⁷ of R&D Planning & Management Function, R&D Div.
Kentaro Asakura	Head* ⁷ of Corporate Communications Dept., Global Corporate Planning & Management	Corporate Officer Head* ⁷ of Corporate Communications Dept., Global Corporate Planning & Management
Tomohiro Kodama	Head* ⁷ of Finance & Accounting Dept., Global Corporate Planning & Management	Corporate Officer Head* ⁷ of Finance & Accounting Dept., Global Corporate Planning & Management
Chiaki Matsumoto	Head* ⁷ of Regulatory Affairs Strategy Dept., Development Function, R&D Div.	Corporate Officer Head* ⁷ of Regulatory Affairs Strategy Dept., Development Function, R&D Div.

*⁵ CxO, Head of Global Corporate Function or Unit Head under Global Management Structure as of April 1, 2025

*⁶ Holding concurrent position as the Unit Head under Global Management Structure

*⁷ The current “Vice President” and “Senior Director” will be referred to as “Head” starting in April.

*⁸ QA: Quality Assurance, CSPV: Clinical Safety & Pharmacovigilance

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.

Media Contact:

Daiichi Sankyo Co., Ltd.

DS-PR_jp@daiichisankyo.com

Investor Relations Contact:

DaiichiSankyoIR_jp@daiichisankyo.com